NEW YORK (GenomeWeb) — BGI Europe has inked an exclusive technology transfer deal with Spain's NIM Genetics for BGI Europe's non-invasive prenatal testing technology.

The deal allows NIM to begin offering BGI Europe's NIPT in Spain. The test, called TrisoNIM Advance and marketed as Nifty in other parts of Europe, detects the risk of genetic conditions such as Down syndrome from as early as 10 weeks into the pregnancy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.